Observational Study on Anti-Tat Immune Response in HIV-1-infected HAART-treated Adult Subjects (ISS OBS T-002)

Clinical Trial ID NCT01024556

PubWeight™ 5.59^‹?›

🔗 Visit the ClinicalTrials.gov page for NCT01024556

Top papers

Rank	Title	Journal	Year	PubWeight™‹?›
1	Trans-activator gene of human T-lymphotropic virus type III (HTLV-III).	Science	1985	12.75
2	Tat protein of HIV-1 stimulates growth of cells derived from Kaposi's sarcoma lesions of AIDS patients.	Nature	1990	4.47
3	Release, uptake, and effects of extracellular human immunodeficiency virus type 1 Tat protein on cell growth and viral transactivation.	J Virol	1993	3.68
4	An inhibitor of HIV-1 protease modulates proteasome activity, antigen presentation, and T cell responses.	Proc Natl Acad Sci U S A	1998	1.50
5	Therapeutic immunization with HIV-1 Tat reduces immune activation and loss of regulatory T-cells and improves immune function in subjects on HAART.	PLoS One	2010	1.13
6	Candidate HIV-1 Tat vaccine development: from basic science to clinical trials.	AIDS	2006	1.12
7	Challenges in HIV Vaccine Research for Treatment and Prevention.	Front Immunol	2014	0.93
8	The presence of anti-Tat antibodies in HIV-infected individuals is associated with containment of CD4+ T-cell decay and viral load, and with delay of disease progression: results of a 3-year cohort study.	Retrovirology	2014	0.92
9	HIV-1 tat promotes integrin-mediated HIV transmission to dendritic cells by binding Env spikes and competes neutralization by anti-HIV antibodies.	PLoS One	2012	0.91
10	HIV-1 Tat immunization restores immune homeostasis and attacks the HAART-resistant blood HIV DNA: results of a randomized phase II exploratory clinical trial.	Retrovirology	2015	0.89
11	Development of a novel AIDS vaccine: the HIV-1 transactivator of transcription protein vaccine.	Expert Opin Biol Ther	2015	0.79